BridgeBio Pharma BBIO Change in Lease Liabilities
Change in Lease Liabilities at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOperatingLeaseLiability.
The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about BridgeBio Pharma's change in lease liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BridgeBio Pharma's change in lease liabilities?
- BridgeBio Pharma (BBIO) reported change in lease liabilities of -$1.85M in Q1 2026.
- How has BridgeBio Pharma's change in lease liabilities changed year-over-year?
- BridgeBio Pharma's change in lease liabilities decreased by 26.0% year-over-year, from -$1.47M to -$1.85M.
- What is the long-term trend for BridgeBio Pharma's change in lease liabilities?
- Over 4 years (2021 to 2025), BridgeBio Pharma's change in lease liabilities has grown at a 1.7% compound annual growth rate (CAGR), from -$6.12M to -$6.55M.
- What does change in lease liabilities mean?
- The change in the company's total lease obligations.
- How do you interpret change in lease liabilities?
- A decrease indicates the company is paying down its lease liabilities, which consumes cash.
- How does change in lease liabilities compare across companies?
- Standard for any company with significant real estate or equipment lease footprints.